Wells Fargo & Company Monte Rosa Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 16,308 shares of GLUE stock, worth $151,012. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,308
Previous 13,219
23.37%
Holding current value
$151,012
Previous $93,000
35.48%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding GLUE
# of Institutions
77Shares Held
40.5MCall Options Held
84.2KPut Options Held
20.6K-
Nea Management Company, LLC Timonium, MD7.69MShares$71.2 Million2.72% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.98MShares$55.4 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$45.5 Million0.24% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.54MShares$42 Million0.23% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.66MShares$24.6 Million0.42% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $433M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...